Former Head of Takeda Ventures to Co‑Lead the Dementia Discovery Funds and Expand U.S. Investment Activities
London and Boston, 9 January 2026 – SV Health Investors ("SV") today announced the appointment of Miles Gerson as Partner. Miles will join the firm based in Boston to invest out of the Dementia Discovery Funds ("DDF”) and to drive the continued expansion of the Funds’ investment activities in the United States.
In his new role, Miles will focus on identifying, building, investing in, and supporting new and existing biotechnology companies developing highly differentiated, disease‑modifying therapeutics and platforms for dementia and related neurodegenerative disorders. He will work closely with DDF portfolio companies at both the strategic and board levels, while also helping to further shape and execute DDF’s long‑term investment strategy.
Kate Bingham, Managing Partner at SV Health Investors, said: “We are delighted to welcome Miles to SV and to the Dementia Discovery Funds. He knows SV well having worked together on several prior co‑investments. Miles brings a rare combination of operating experience and venture investing expertise, which will be invaluable as we continue to grow DDF and invest in companies developing innovative approaches for patients suffering from dementia.”
Miles Gerson, Partner at SV Health Investors, added: “I am excited to join SV at a time when there is an urgent need for new, truly disease‑modifying treatments for neurodegenerative disorders. DDF’s focused strategy, strong scientific foundation, and company creation model uniquely position it to translate cutting‑edge science into meaningful therapies for patients. I look forward to working with the investment team and the Funds’ portfolio companies to advance these important programs.”
Prior to joining SV, Miles served as Head of Takeda Ventures, where he led the corporate venture capital group’s global investment strategy across early‑stage biotechnology companies and enabling platform technologies. During his tenure, he was responsible for sourcing, executing, and managing investments aligned with Takeda’s R&D priorities, and for working closely with portfolio companies at the board and strategic levels. His background spans venture capital, business development, and the creation and scaling of innovative life science companies. Miles holds a JD/MBA as well as a Master’s in Neuroscience.
Since its inception in 2018, and following the close of its second fund, DDF‑2, in May 2025 at $269 million, the Dementia Discovery Funds have reinforced their position as a leader in dementia‑focused venture investing. DDF has built a portfolio of more than 20 companies, pursuing over 60 novel and differentiated therapeutic approaches across multiple forms of dementia, including Alzheimer’s disease, with more than seven companies now at the clinical stage.
About SV Health Investors’ Dementia Discovery Fund
SV Health Investors’ Dementia Discovery Fund (DDF) is the world’s largest family of specialized venture capital funds that invests exclusively in companies developing or enabling novel therapeutics for dementia. Dementias including Alzheimer’s Disease are arguably the largest unmet medical need with over 55m patients worldwide. With more than $600m raised for this strategy, and offices in London and Boston, DDF capitalizes on global investment opportunities to fulfill its dual mandate of delivering measurable impact and generating significant financial returns. Utilizing its network of venture partners, entrepreneurs, leading scientists, and strategic partners, DDF invests in and creates new biotech companies and provides thought leadership in the field. DDF is enabled by its cornerstone investors AARP, British Business Bank and Gates Frontier, as well as additional limited partners, including major pharmaceutical companies and leading non-profits. For more information, please visit https://svhealthinvestors.com/....
About SV Health Investors
SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. The SV funds invest across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, medical devices, healthcare growth and healthcare technology. With approximately $2bn in assets under management and a truly transatlantic presence with offices in London and Boston, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in, created and built more than 200 companies attracting global talent, entrepreneurs and pharma partners. To date, these investments have resulted in the licensing of 28 novel drugs and six new drug classes able to treat indications with unmet medical needs and deliver positive impact to patients.
